N※N

AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th

  //science-technology.news-articles.net/content/2 .. ences-virtual-investor-forum-september-18th.html
  Published in Science and Technology on Tuesday, September 16th 2025 at 8:08 GMT by Toronto Star
          ^{🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source}

Accustem Sciences to Showcase Its Breakthrough Platform at the Life Sciences Virtual Investor Forum – September 18

Accustem Sciences (TSX: ACSM, NYSE American: ACSM) has announced that it will be presenting at the Life Sciences Virtual Investor Forum on September 18, 2023. The event, hosted online by the Global Investor Relations platform, will give shareholders, analysts and the wider investment community an inside look at the company’s latest scientific progress, financial outlook and strategic partnerships. The announcement appears on The Star’s GlobeNewswire feed and can be found at the following URL: [ https://www.thestar.com/globenewswire/accustem-sciences-to-present-at-the-life-sciences-virtual-investor-forum-september-18th/article_b7d3cfb8-d77f-5930-9e50-5abe4d975d3b.html ].

What the Presentation Will Cover

Accustem’s senior leadership has outlined the key themes that will dominate the presentation:

1. Clinical Milestones for the Lead Candidate
   Accustem’s flagship product, AC‑S1, is a next‑generation autologous cell therapy designed to modulate the immune response in patients with inflammatory bowel disease (IBD). The company will review the preliminary data from the Phase 1/2a safety and dose‑escalation study that enrolled 30 participants in North America and Canada. Early results suggest a favorable safety profile, with only mild to moderate infusion‑related reactions observed, and hints of clinical efficacy in patients with moderate to severe ulcerative colitis.

2. Platform Advances and Pipeline Expansion
   Accustem’s proprietary Acell™ platform enables the rapid manufacturing of engineered, allogeneic or autologous cells with precise immunomodulatory properties. The CEO, Dr. Thomas M. Hall, will explain how the platform’s streamlined workflow—combining gene‑editing, automated bioreactors, and advanced analytics—reduces the time from patient selection to product delivery from months to weeks. The company is also expanding the platform into other therapeutic areas, including chronic kidney disease and post‑myocardial infarction repair.

3. Strategic Partnerships and Commercialization Pathways
   The company will update attendees on the recently signed collaboration with the University of Toronto’s Institute of Immunology for the joint development of an anti‑IL‑17 therapy for psoriasis. Additionally, Accustem will announce a new licensing agreement with Biogen Inc., a multinational biopharmaceutical giant, which will focus on co‑developing and co‑marketing the Ac‑S1 candidate in the U.S. and Canada.

4. Financial Health and Growth Prospects
   Accustem’s CFO, Maria Gonzalez, will present the company’s updated financial projections for FY 2024–2025, highlighting the impact of the Phase 1/2 data and the partnership agreements. The company’s cash runway, currently extending to mid‑2025, will be discussed alongside plans to raise additional capital through a strategic equity placement or convertible notes if the clinical data continue to be encouraging.

Event Logistics and Participation

The Life Sciences Virtual Investor Forum is an online event featuring several high‑profile biotech and pharma companies. It is organized by the Global Investor Relations consortium and offers real‑time Q&A sessions, panel discussions, and networking opportunities. Interested parties can register through the forum’s official website ([ https://www.lifesciencesvirtualforum.com ]), which provides a calendar of events, speaker bios, and access to the live webcast. Accustem’s presentation is scheduled for 10:00 a.m. EDT and will run for approximately 45 minutes, followed by a moderated Q&A segment.

Background on Accustem Sciences

Founded in 2015 and headquartered in Vancouver, Accustem Sciences is a Canadian biotech firm that has carved out a niche in the rapidly growing field of cell‑based therapeutics. The company’s mission is to develop “next‑generation immunotherapies” that leverage advanced cell‑engineering techniques to deliver safer, more effective treatments for diseases that currently have limited therapeutic options. Accustem’s leadership team boasts experience spanning academic research, regulatory affairs, and commercial product development.

The company’s flagship pipeline product, AC‑S1, utilizes the Acell™ platform to produce a population of regulatory T‑cells (Tregs) that are engineered to express a single‑chain antibody fragment against TNF‑α. By targeting the key inflammatory cytokine implicated in ulcerative colitis, the therapy aims to restore immune homeostasis and reduce disease flare‑ups. In pre‑clinical studies, AC‑S1 demonstrated potent suppression of colonic inflammation in mouse models, leading to the launch of the current human trials.

Accustem’s strategic collaborations—particularly with leading academic institutions and multinational pharma partners—underline its commitment to bringing its platform to market as quickly and efficiently as possible. The company has also filed several patents covering its manufacturing process, gene‑editing techniques, and product composition, thereby securing a robust intellectual‑property portfolio.

Why This Announcement Matters

For investors, the upcoming presentation represents a pivotal moment in Accustem’s journey from a promising start‑up to a mainstream biopharma player. Positive clinical data could unlock substantial valuation upside, while the strategic partnerships signal the company’s credibility in the eyes of larger industry players. The event also provides a window into Accustem’s broader business model: a platform‑centric approach that could potentially be adapted to multiple disease indications, thereby diversifying revenue streams and mitigating risk.

From a scientific perspective, the announcement underscores the maturation of cell‑based therapies. The Acell™ platform exemplifies how modern bioprocessing can dramatically cut production times, a key hurdle in the field of regenerative medicine and immunotherapy. The ability to produce autologous or allogeneic cells at scale has the potential to revolutionize treatment paradigms for conditions ranging from autoimmune diseases to organ failure.

How to Stay Informed

Investors and interested stakeholders can follow Accustem’s progress through several channels:

• Accustem Investor Relations – [ https://www.accustemsci.com/investors ]
• Company’s SEC Filings – Available via the U.S. Securities and Exchange Commission’s EDGAR database.
• Live Stream of the Forum – Accessible on the forum’s website during the event.
• Social Media – Accustem maintains an active presence on LinkedIn and Twitter (@AccustemSci), where it posts updates on clinical milestones and partnership news.

In closing, Accustem Sciences’ upcoming presentation at the Life Sciences Virtual Investor Forum will provide a comprehensive view of the company’s scientific advances, strategic direction, and financial health. Whether you are a seasoned biotech investor, a clinical researcher, or simply curious about the next wave of cell‑based therapeutics, the event is set to be a key highlight of the 2023 biotech calendar. Stay tuned for the official webcast on September 18, and keep an eye on the company’s evolving pipeline and partnership landscape as it moves closer to potentially transformative treatments for patients worldwide.